Introduction: Mucopolysaccharidosis VI is a rare disease characterized by the
responsible for many different clinical manifestations, such as valvular heart disease, abnormal liver and spleen sizes, range of joint motion reduction, growth retardation, multiple dysostosis, and corneal opacification. 1, 2 It is estimated that the world incidence of MPS VI is approximately from 1:248,000 to 1:320,000 live births. 3, 4 The treatment of MPS VI consists of enzyme replacement therapy (ERT), involving intravenous infusion of galsulfase. In relation to the effectiveness and safety of the treatment with galsulfase, two systematic reviews, including randomized and quasi-randomized clinical trials, assessed the theme 5, 6 and indicated that galsulfase is safe and efficacious to improve patient's resistance and the reduction of urinary GAG. 5, 6 However, the outcomes assessed by the studies were limited due to fact that there was no report of different clinical manifestations associated to the disease, such as heart function, range of joint motion, and quality of life. The best evidence found in two systematic reviews refer to the same clinical trial published in 2006, 7 and another clinical trial 8 included only in one systematic review. 6 In this context, although randomized clinical trials were on the top of evidence hierarchy, it is not possible to assure that these trials could answer to certain research questions; therefore, other approaches are recommended to analyze different dimensions of a clinical outcome. 9, 10 In this respect, observational researches are extremely useful to investigate the effectiveness of a technology. This kind of study is particularly important to the analysis of health outcomes about rare diseases when using patients' records and electronic databases on health that offer important clinical information.
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The aim of this research is to conduct a systematic review of observational studies that assess the effectiveness and safety of the enzyme replacement therapy with galsulfase in order to verify the long-term treatment effect without ideal conditions, such as controlled and randomized clinical trials, since previous systematic reviews included a 24-week follow-up clinical trial. Thus, this study intends to systematize evidence and to contribute with a research related to therapy effectiveness taking into account the lack of studies on the theme.
| METHODS

| Register and protocol
This study was registered at Prospero (International Prospective Register of Systematic Reviews) under the number CRD42017056408.
| Eligibility criteria
We included observational studies that assessed clinical outcomes after the administration of enzyme replacement therapy with galsulfase compared with no treatment, placebo, or usual care with MPS VI patients of any age or gender. The studies excluded were those that did not present specific results in relation to MPS VI, those that included patients subjected to previous hematopoietic stem cell transplantation, and those that reported any outcome without presenting data on clinical characteristic of patients before and after therapy administration. In addition, when different studies clearly assessed the same clinical trial and group of patients in different periods of time, we opted to include only the most recent studies in this systematic review. There was no restriction by language and publication date.
| Information on sources and search strategy
The literature search for eligible studies was performed on October 25, 2016, and updated on March 19, 2018 , in the databases MEDLINE (via PubMed), Cochrane Library, and Lilacs. Moreover, a search was made in the Journal of Inherited Metabolic Disease and manual search was made in reference quotes. The search strategy was developed using the terms MeSH (Medical Subject Heading) at PubMed and a keyword combination. The search includes the terms "Mucopolysaccharidosis VI," "Arylsulfatase B Deficiency," "Maroteaux-Lamy Syndrome," "Mucopolysaccharidosis Type VI," "Mucopolysaccharidosis Type 6," "N-Acetylgalactosamine-4-Sulfatase Deficiency," "Polydystrophic Dwarfism," "ARSB Deficiency," "Enzyme Replacement Therapy," "galsulfase," "Recombinant Proteins," and "NAcetylgalactosamine-4-Sulfatase." The search strategies were adapted according to specificities of each database (Table S1 ).
| Study selection
The study selection process was conducted independently by two evaluators (DFG and LGG). At a first stage, after removing the duplicates, titles and summaries were assessed. At a second stage, the selected studies were fully read, and those which fulfilled the eligibility criteria were selected for data mining and quality assessment. Disagreements on both stages were solved by consensus.
| Data mining and quality assessment of studies
Data mining was conducted independently by two authors (DFG and LGG) by using standardized spreadsheets. Disagreements were solved by consensus. Extracted data included characteristics of the studies, sample size, and characterization of outcomes.
Quality assessment of the studies was also independently conducted (DFG and LGG). For cohort study assessment, longitudinal study, and case-control study, Newcastle-Ottawa tool 12 was used. It consists of the attribution of up to nine stars to quality criteria, being organized in three dimensions (study selection, group comparability, and outcomes). For cross-sectional study, case series, and case report, checklists developed by Joanna Briggs Institute (JBI) were used aiming at each study design. [13] [14] [15] The tools developed by JBI assess each quality criterion as "yes," "no," or "uncertain."
| Data analysis
The effectiveness of enzyme replacement therapy in MPS VI patients was identified by a qualitative assessment of each study report. The outcomes were classified as primary and substitute according to the authors' assessment. In addition, mean age at diagnosis, mean age at initiation of therapy, average duration of treatment, and mean duration of follow-up data were collected.
3 | RESULTS
| Study selection
The literature search found 495 records. After removing duplicates, 446 records were selected for title and abstract evaluation. Thus, 69 records were considered to be potentially eligible and were fully read. Among those records, 18 studies were included in the systematic review. Figure 1 shows details on the selection process and reasons for study exclusion.
| Study characteristics
Among the 18 observational studies included, 2 were cohort studies, 1 was longitudinal study, 1 was cross-sectional study, 1 was case-control, 8 were case series, and 5 were case reports. A total of 362 participants were included in the review. Nonetheless, there were 4 multicenter studies, [16] [17] [18] [19] and some studies were conducted in the same reference center; overlap of participants could be possible. Twelve studies included only MPS VI patients who received enzyme replacement therapy, and the other studies included patients with different types of mucopolysaccharidosis, including a MPS VI. [20] [21] [22] [23] [24] [25] The mean age at diagnosis was 4.4 years, varying from the moment after childbirth to 6.7 years old; the mean age at initiation of treatment was 8.8 years, varying from 6 weeks to 17.2 years old. The average duration of treatment was 49.8 months (from 1 to 120 months), and the mean duration of patient follow-up was 51 months (from 6 to 120 months). Table 1 shows the main characteristics of the studies.
In general, the studies were classified with moderate to high quality, being assessed by star rating (cohort and casecontrol studies) or "yes" answers (cross-sectional, case series, and case report studies). The meta-analysis could not be conducted because the studies did not report association measures. Quality assessment of each study is shown in Table S2 .
| CLINICAL OUTCOMES
The effectiveness of the enzyme replacement therapy in MPS VI patients was associated to fourteen clinical outcomes. From these outcomes, six were considered primary and eight were considered substitute outcomes. The three outcomes most assessed were related to heart function (10/18), concentration of urinary GAG (10/18), and respiratory function (7/18). Only one study assessed mortality/survival (Table 2) . Table 3 presents a summary on the effect of treatment for each outcome. The studies showed that the enzyme replacement therapy had a positive effect on the patient's survival outcomes (mortality), 16 quality of life specific domains, 16, 26 lung function improvement, 16, 17, 19, 23, 26 increased range of joint motion (joint mobility), 19, 22, 24, [26] [27] [28] physical resistance improvement, [16] [17] [18] [19] 29 reduction of urinary GAG, [16] [17] [18] [19] [26] [27] [28] [29] [30] and growth. [16] [17] [18] 28, 29 Regarding quality of life (2/18), different tools were used, limiting data comparison. 16, 26 Generally, the tools reported improvement in the domain "functioning and body functioning" while the domains "anxiety" and "negative emotions" did not show any improvement. The treatment showed positive association with survival (unadjusted Hazard Ratio, 0.24; 95% CI, 0.10-0.59). 16 The hearing function 17, 18, 26, 28, 29 and the cognitive development remained stable after treatment. 31 The other outcomes related to cardiac function, visual acuity, sleep apnea, and the size of the liver and spleen presented inconclusive results (Table 3 ). Regarding safety, some studies (4/5) reported light adverse events mainly related to reactions of hypersensitivity, such as mild allergic reactions, urticaria, and pyrexia-which were controlled after the reduction of drug infusion rates or with the administration of antihistamines before each infusion. 17, 18, 20, 29 Among primary outcomes, the studies that assessed the cardiac function presented inconclusive results. Some studies (4/10) suggest that the treatment caused changes in the cardiac dimensions, 19, 26, 32, 33 assessed according to some parameters, such as left ventricular dimension at end diastole (LVED), left ventricular shortening fraction (LVSF), left ventricular septal (LVSW), or posterior wall thickness (LVPW). Other studies reported that there is no significant change in the evaluated cardiac parameters (5/10), 16, 17, [27] [28] [29] and one study presented inconclusive results (1/10). 18 
| DISCUSSION
In general, the studies included in this systematic review point out that ERT eases the severity on clinical outcomes of MPS VI. Among the primary outcomes, the treatment had an effect on patient's survival, quality of life in some specific domains, lung function, increased range of joint motion, and physical resistance improvement. This was the first systematic review focusing on the effectiveness of ERT with galsulfase from the analysis of observational studies. Previous systematic reviews, including randomized clinical trials, verified that ERT with galsulfase is safe and efficacious in the patient's physical resistance improvement and in the reduction of urinary GAG. 5, 6 Fourteen outcomes related to ERT in MPS VI patients were identified in this study review. Hitherto, two systematic reviews assessed only three parameters: physical resistance, urinary GAG concentration, and safety. 5, 6 The restriction of the outcomes assessed until now limits strong evidence once other outcomes can be relevant from the patient's perspective. Few studies reported the effect of the treatment on mortality and quality of life, highlighting the need for further researches. Concerning quality of life, different tools were used, limiting the comparison of data. Therefore, it is recommended that a standard instrument for assessing quality of life in rare diseases be developed.
Regarding cardiac function, the effect was uncertain, since four different findings were reported by the studies. As MPS VI is associated with a number of cardiac manifestations, the discrepancy of the findings can be attributed to the different cardiac measures assessed in each study, such as the left ventricular diastolic diameter, the thickness of the ventricular septum in diastole, and heart valve functioning, hindering the precise description of this outcome. The sample size indicates the number of patients with MPS VI who received therapy on the total number of the sample.
b Cohort and case-control studies were evaluated by the Newcastle-Ottawa scale, and cross-sectional studies, case series, and case reports were evaluated by tools developed by Joanna Briggs Institute, specific for each type of study.
c Follow-up data were available for four patients with MPS VI undergoing enzyme replacement therapy. Hendriksz et al 17 Liver and spleen size were considered normal at baseline and remained static.
T A B L E 2 Clinical outcomes assessed for study
But et al 27 Progression of liver and spleen size.
Furujo et al 28 Reduction or stabilization of liver and spleen size.
Lin et al 19 Inconclusive data on the effect of treatment on the liver and spleen, but the majority of the evaluated patients remained unchanged. Ebbink et al 31 Among the six studies evaluating respiratory function, two did not show differences after ERT intervention. 27, 29 The first is a case report of two patients, and the effect of ERT on pulmonary function could be assessed in only one of the patients, due to clinical complications. The second study evaluated pulmonary function pre and post ERT in four patients, and only one patient had a progression on obstructive disease; two patients were adults by ERT initiation; therefore, their clinical status had already progressed.
Two studies reported that there was no statistically significant effect on joint mobility. During treatment, one study reported improvement only in shoulder flexion, while there was an insignificant improvement in the range of motion of the hip, knee, and elbow. The authors raise three possible hypotheses for this result: first, the surface area of the glenoid is smaller than that of the hip, since the glenoid is made of cartilage (including GAGs), it is possible that the damage caused by lysosomal storage is confined to a smaller area and that improvements with ERT are achieved more easily; second, the shoulder is less affected by weight-bearing forces than the hip; and third, the hip joint to ERT may lie in the fact that the anatomical structure of the acetabulum is abnormal at an early age in MPS VI. 26 Another study that presented severe joint limitations before the age of 5 years did not identify any statistically significant differences in knee and hip movements before and after ERT. 29 In visual acuity, different tools were used in the evaluation of the outcome, which may have generated four different findings. Within the ophthalmologic findings, the studies evaluated visual acuity, opacification of the cornea, and morphological findings of the eye and optic nerve. Only one case report showed progression of corneal opacification 28 in which a patient presented normal ophthalmology data at baseline and progressed to mild corneal clouding after 36 weeks of treatment. It is interesting to note that in the visual acuity, no study reported a positive treatment effect. Sleep apnea was evaluated by two studies and there was mixed results. One case report showed that ERT was effective on reducing continuous positive airway pressure, but only for one patient (the second patient suffered from clinical complications and could not be evaluated). 27 One study showed inconclusive data on the effect of ERT for sleep apnea; there was no report how the outcome was evaluated, and there was limited patient's data for a conclusion regarding ERT intervention effect. Although this study included only 59 participants, survival analysis was not limited to these participants. Survival data included participants who were already being evaluated in a previous study, including 117 participants.
The majority of studies evaluating liver and spleen sizes showed that these parameters remained or decreased after follow-up period. Otherwise, in a case report study included in this review, both patients evaluated had a progression on both liver and spleen sizes after 10 years of ERT 28 ; the lack of data in the study regarding these clinical characteristics hinders the understanding of discrepancies between studies.
Among the ten studies that evaluated urinary GAG concentration, only one study 33 reported an increase in urinary GAG level after initiation of treatment. It is interesting to note that the two patients evaluated in this study lost five consecutive infusions of the 20 infusions proposed for the evaluation period. Light adverse events were observed in this review, for example, mild allergic reactions, urticaria, skin rash, local edema, chills, pyrexia, and feeling hot. Those events were controlled after the reduction of drug infusion rates or with the administration of antihistamines before each infusion.
There are several discrepancies between studies included that need to be considered in this evaluation. The cohort studies did not represent conventional comparator groups, i.e., MPS VI patients who had not received the intervention, neither were introduced to statistical data, especially association measures. Nevertheless, it is known that observational studies on rare diseases endure important challenge, such as absence of appropriate comparison group and difficulty to control confounding because risk factors are generally not very well understood. 11 Other limitations were found and compromised the assessment of treatment effect. The studies presented a small sample size, what may cause risk of bias because of bias in data collection and interpretation. Due to absence of association measures, it was not possible to make meta-analysis. During the process of data collection, identifying the number of participants assessed by outcome was hindered since many studies assessed different outcomes or included different kinds of MPS.
Multicenter studies are already being developed and can support the conducting of research with a bigger sample size and better methodological quality. The study Clinical Surveillance Program, 17 for example, is a multinational and multicenter record in progress that could bring robust results.
| CONCLUSION
The findings indicated that the enzyme replacement therapy with galsulfase has some positive effect on changing the natural course of mucopolysaccharidosis VI. However, new studies with better methodological quality should be conducted. Hitherto, scientific evidence about the treatment is fragile, indicating that the intervention brings some benefits to MPS VI patients, but not providing conclusive results on the treatment due to methodological limitations.
